Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …

Background The promise of precision cancer medicine presently centers around the
genomic sequence of a patient's tumor being translated into timely, actionable information to …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

Abstract Characterization and integration of the genome, epigenome, transcriptome,
proteome and metabolome of different datasets is difficult owing to a lack of ground truth …

Detecting mutations from single DNA molecules is crucial in many fields but challenging.
Next-generation sequencing (NGS) affords tremendous throughput but cannot directly …

We report a personalized tumor-informed technology, Patient-specific pROgnostic and
Potential tHErapeutic marker Tracking (PROPHET) using deep sequencing of 50 patient …

In the current era of precision medicine, the identification of genomic alterations has
revolutionised the management of patients with solid tumours. Recent advances in the …

Background Liquid biopsy (LB) is a rapidly evolving diagnostic tool for precision oncology
that has recently found its way into routine practice as an adjunct to tissue biopsy (TB). The …

The low abundance of circulating tumour DNA (ctDNA) in plasma samples makes the
analysis of ctDNA biomarkers for the detection or monitoring of early-stage cancers …

Liquid biopsy has been established as a powerful, minimally invasive, tool to detect clinically
actionable aberrations across numerous cancer types in real-time. With the development of …